{"filing":{"accession_number":"0001213900-26-070172","cik":"0001584371","ticker":"ICCM","company_name":"IceCure Medical Ltd.","form":"6-K","filing_date":"2026-06-18","report_date":null,"primary_document":"ea0295200-6k_icecure.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1584371/000121390026070172/ea0295200-6k_icecure.htm"},"events":[{"id":12094,"run_id":10656,"accession_number":"0001213900-26-070172","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"IceCure announced 70% growth in its U.S. commercial install base for ProSense® breast cancer cryoablation systems following FDA clearance in October 2025, driven by increased physician demand and clinical guideline support from the American Society of Breast Surgeons.","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-06-18","form":"6-K","submitted_at":null,"items":[{"id":8849,"accession_number":"0001213900-26-070172","item_number":"EX-99.1","item_title":"ea029520001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a 70% growth in IceCure's U.S. commercial install base for ProSense® breast cancer cryoablation systems following FDA clearance in October 2025, along with increased physician demand and clinical guideline support from the American Society of Breast Surgeons. While the disclosure reports significant commercial momentum and market adoption metrics, it does not constitute a formal earnings release with financial results, nor does it fit other specific event categories. The announcement is material to investors as it demonstrates accelerating commercial traction and market acceptance of a key product line, but is best classified as an operational/commercial milestone rather than a financial or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T19:02:17.714743+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":12095,"run_id":10656,"accession_number":"0001213900-26-070172","anchor_item_number":"EX-99.2","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"IceCure completed a $5.5 million private placement of 1,833,334 ordinary shares plus Series D and E Warrants to a healthcare-focused institutional investor at $3.00 per share, issued under Section 4(a)(2) exemption.","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-06-18","form":"6-K","submitted_at":null,"items":[{"id":8850,"accession_number":"0001213900-26-070172","item_number":"EX-99.2","item_title":"ea029520001ex99-2.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"IceCure announced a $5.5 million private placement of 1,833,334 ordinary shares plus Series D and E Warrants to a single healthcare-focused institutional investor at $3.00 per share, priced at a premium to market. The securities are unregistered and issued under Section 4(a)(2) exemption. This is a classic dilutive equity issuance that materially affects shareholder ownership and capital structure, particularly given the warrant components and the company's apparent need for working capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T19:02:17.714743+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8849,"accession_number":"0001213900-26-070172","item_number":"EX-99.1","item_title":"ea029520001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a 70% growth in IceCure's U.S. commercial install base for ProSense® breast cancer cryoablation systems following FDA clearance in October 2025, along with increased physician demand and clinical guideline support from the American Society of Breast Surgeons. While the disclosure reports significant commercial momentum and market adoption metrics, it does not constitute a formal earnings release with financial results, nor does it fit other specific event categories. The announcement is material to investors as it demonstrates accelerating commercial traction and market acceptance of a key product line, but is best classified as an operational/commercial milestone rather than a financial or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T19:02:17.714743+00:00","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-06-18"},{"id":8850,"accession_number":"0001213900-26-070172","item_number":"EX-99.2","item_title":"ea029520001ex99-2.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"IceCure announced a $5.5 million private placement of 1,833,334 ordinary shares plus Series D and E Warrants to a single healthcare-focused institutional investor at $3.00 per share, priced at a premium to market. The securities are unregistered and issued under Section 4(a)(2) exemption. This is a classic dilutive equity issuance that materially affects shareholder ownership and capital structure, particularly given the warrant components and the company's apparent need for working capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T19:02:17.714743+00:00","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-06-18"}]}